• No results found

University of Groningen Improving antimicrobial therapy for Buruli ulcer Omansen, Till Frederik

N/A
N/A
Protected

Academic year: 2021

Share "University of Groningen Improving antimicrobial therapy for Buruli ulcer Omansen, Till Frederik"

Copied!
3
0
0

Bezig met laden.... (Bekijk nu de volledige tekst)

Hele tekst

(1)

University of Groningen

Improving antimicrobial therapy for Buruli ulcer

Omansen, Till Frederik

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version

Publisher's PDF, also known as Version of record

Publication date: 2019

Link to publication in University of Groningen/UMCG research database

Citation for published version (APA):

Omansen, T. F. (2019). Improving antimicrobial therapy for Buruli ulcer: Pre-clinical studies towards highly efficient, short-course therapy. University of Groningen.

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

(2)

161 List of publications

lIsT OF puBlICaTIOns

- Almeida DV, Omansen TF, Li SY, Lee J, Grosset JH, Converse PJ, Nuermberger EL.

Oxa-zolidinones Can Replace Clarithromycin in Combination with Rifampin in a Mouse Model of Buruli Ulcer. Antimicrob Agents Chemother. 2019 Feb 26;63(3). pii: e02171-18. - Omansen TF, Stienstra Y, van der Werf TS. Treatment for Buruli ulcer: the long and

wind-ing road to antimicrobials-first. Cochrane Database Syst Rev. 2018 Dec 17;12:ED000128. - Omansen TF, Almeida D, Converse PJ, Li SY, Lee J, Stienstra Y, van der Werf T, Grosset

JH, Nuermberger EL. High-Dose Rifamycins Enable Shorter Oral Treatment in a Murine Model of Mycobacterium ulcerans Disease. Antimicrob Agents Chemother. 2019 Jan 29;63(2). pii: e01478-18.

- Beeres DT, Ravensbergen SJ, Heidema A, Cornish D, Vonk M, Wijnholds LD, Hendriks JJH, Kleinnijenhuis J, Omansen TF, Stienstra Y. Efficacy of ivermectin mass-drug

administra-tion to control scabies in asylum seekers in the Netherlands: A retrospective cohort study between January 2014 - March 2016. PLoS Negl Trop Dis. 2018 May 17;12(5):e0006401. - Ammerman NC, Swanson RV, Bautista EM, Almeida DV, Sani V, Omansen TF, Guo H,

Chang Y, Li SY, Tapley A, Tasneen R, Tyagi S, Betoudji F, Moodley C, Ngcobo B, Pillay L, Bester LA, Singh SD, Chaisson RE, Nuermberger E, Grosset JH. Impact of clofazimine dos-ing on treatment-shortendos-ing of the first-line regimen in a mouse model of tuberculosis. Antimicrob Agents Chemother. 2018 Jun 26;62(7). pii: e00636-18.

- Wallace JR, Mangas KM, Porter JL, Marcsisin R, Pidot SJ, Howden B, Omansen TF, Zeng

W, Axford JK, Johnson PDR, Stinear TP. Mycobacterium ulcerans low infectious dose and mechanical transmission support insect bites and puncturing injuries in the spread of Buruli ulcer. PLoS Negl Trop Dis. 2017 Apr 14;11(4):e0005553.

- Gröschel MI, Omansen TF, de Lange W, van der Werf TS, Lokate M, Bathoorn E,

Ak-kerman OW, Stienstra Y. Multidrug-Resistant Tuberculosis Complicated by Nosocomial Infection with Multidrug-Resistant Enterobacteriaceae. Am J Trop Med Hyg. 2016 Jan 11. - Omansen TF, Porter JL, Johnson PD, van der Werf TS, Stienstra Y, Stinear TP. In-vitro

Activity of Avermectins against Mycobacterium ulcerans. PLoS Negl Trop Dis 2015 Mar 5;9(3):e0003549.

(3)

162

List of publications

- Glasner C, van Timmeren MM, Stobernack T, Omansen TF, Raangs EC, Rossen JW, et

al. Low anti-staphylococcal IgG responses in granulomatosis with polyangiitis patients despite long-term Staphylococcus aureus exposure. Sci Rep 2015 Feb 2;5:8188.

- de Zeeuw J, Douwstra M, Omansen TF, Sopoh GE, Johnson C, Phillips RO, et al.

Psycho-metric Properties of the Participation Scale among Former Buruli Ulcer Patients in Ghana and Benin. PLoS Negl Trop Dis 2014 Nov 13;8(11):e3254.

- de Zeeuw J, Omansen TF, Douwstra M, Barogui YT, Agossadou C, Sopoh GE, et al.

Persist-ing Social Participation Restrictions among Former Buruli Ulcer Patients in Ghana and Benin. PLoS Negl Trop Dis 2014 Nov 13;8(11):e3303.

- de Zeeuw J, Duggirala S, Nienhuis WA, Abass KM, Tuah W, Omansen TF, et al. Serum

levels of neopterin during antimicrobial treatment for Mycobacterium ulcerans infection. Am J Trop Med Hyg 2013 Sep;89(3):498-500.

- van der Kooi-Pol MM, Sadaghian Sadabad M, Duipmans JC, Sabat AJ, Stobernack T, Omansen TF, et al. Topography of distinct Staphylococcus aureus types in chronic

wounds of patients with epidermolysis bullosa. PLoS One 2013 Jun 25;8(6):e67272

Other publications:

- Omansen TF, Völker K, Ramharter M. Larva migrans cutanea – an important visual

diag-nosis amongst returning travellers. Flug u Reisemed 2019; 26(01): 6-8. DOI: 10.1055/a-0815-9139

- Omansen TF, Grout L, Asiedu K. Results of the 2017 global WHO survey on yaws. Weekly

Epidemiological Record, 17 August 2018, vol. 93, 33 (pp. 417–423)

- Omansen TF, Grout L, Gabrielli AF, Asiedu K. Results of the 2017 global WHO survey on

Referenties

GERELATEERDE DOCUMENTEN

Following on from reports that avermectins have activity against Mycobacterium tuberculosis, we tested the in-vitro efficacy of ivermectin and moxidectin on M.. We observed

Accumulation observed as increasing trough concentrations after several days of IVM administration (FIG 1C) as well as the previously reported lipophilicity and accumulation

Figure 1: Median of footpad swelling grade of infected mouse footpads in response to treatment with high-dose rifamycins and clarithromycin.. Treatment was initiated 6 weeks

In this experiment, we compared the efficacy of these oxazolidinones, including a reduced dose of LZD, in combination with RIF to that of standard-of-care regimens based on their

ulcerans BALB/c mouse model that yielded high- dose rifampin as high-potential candidate regimen for further evaluation of future highly active, short-course regimen to treat BU,

Three research items should to be addressed concerning BU therapy: a) the dosing and pharmacokinetics of the current RIF+CLR regimen should be further explored and optimized, b)

Ivermectine wordt hoofdzakelijk gebruikt in lage, enkelvoudige doses voor de behandeling van parasitaire ziekten, maar zou dagelijks in hogere doses moeten worden toegediend

I would also like to thank all my other teachers, mentors, colleagues and peers in medical school and science that I have met along the way I would like to especially acknowledge the